Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28661171 | 0.86 | CYP19A1 (0.72) | SMN1; SMN2LMNAMAPTFFAR4CYP19A1 | |
| SCHEMBL5289106 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAHTR6MAPTFFAR4 | |
| SCHEMBL7823465 | 0.85 | HTR6 (0.88) | SMN1; SMN2LMNAHTR6MAPTCYP19A1 | |
| SCHEMBL7564170 | 0.85 | GAA (0.76) | SMN1; SMN2LMNAMAPTFFAR4CYP19A1 | |
| SCHEMBL806437 | 0.85 | GAA (0.76) | SMN1; SMN2LMNAMAPTFFAR4CYP19A1 | |
| SCHEMBL8752452 | 0.85 | PGR (0.67) | SMN1; SMN2LMNAHTR6MAPTCYP19A1 | |
| SCHEMBL30434229 | 0.85 | GAA (0.76) | SMN1; SMN2LMNAMAPTFFAR4CYP19A1 | |
| SCHEMBL31681290 | 0.82 | CYP19A1 (0.67) | SMN1; SMN2LMNAMAPTCYP19A1PKM | |
| SCHEMBL2117686 | 0.82 | FFAR4 (0.61) | LMNAMAPTFFAR4CYP19A1PKM | |
| SCHEMBL6933571 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHTR6MAPTFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260097-B | 5-Methylphenidate compound and application thereof in preparation of drugs or probes for reducing or detecting thioredoxin reductase level | 兰州大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-115260097-A | 5-methylphenanthridine compound and application thereof in preparing drug or probe for reducing or detecting thioredoxin reductase level | 兰州大学 | 2022-11-01 | — | — | CN | disclosed |
| US-7446229-B2 | Bicyclic cannabinoids | UNIVERSITY OF CONNECTICUT (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446229-B2 | Bicyclic cannabinoids | UNIVERSITY OF CONNECTICUT (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446229-B2 | Bicyclic cannabinoids | UNIVERSITY OF CONNECTICUT (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | UNIVERSITY OF CONNECTICUT | 2007-06-14 | — | — | US | disclosed |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | UNIVERSITY OF CONNECTICUT | 2007-06-14 | — | — | US | disclosed |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | UNIVERSITY OF CONNECTICUT | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | CNR2, CNR1, FAAH | SMN1; SMN2 3535/4885LMNA 3524/4885HTR6 204/4885 |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | CNR2, CNR1, GPR18 | SMN1; SMN2 3137/4885LMNA 3186/4885HTR6 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.